Background. The aim of this study was to evaluate radiation therapy (RT) productivity, capacity, and cost in Lithuania.
INTRODUCTION
In Lithuania, as in all developed and developing countries, the number of new cancer cases increases every year -in 10 years (2002-2012) the number of oncology patients increased by 23%; the index of new cases of cancer per 100 thousand citizens increased by more than 42% (1) . It is partially linked to the ageing population -in 2012, 52% of new cancer cases in Lithuania were diagnosed for patients 55-74 years of age and 29.5% for patients older than 75 (1) . It is expected that in 2030 almost 1/3 (28.9%) of citizens will be elderly people (2) . These population changes will further contribute to cancer incidence and the demand for RT services over the next decades.
Approximately half of the cancer patients require radiation treatment at some time during the course of their illness. Some recent studies (3) (4) (5) suggest that the optimal RT utilisation rate varies from 40.6% in England to 53.4% in Poland. But since 2005 most of the publications quote the results of the Delaney et al. (6) study which indicated that 52.3% of all people with notifiable malignancies would require RT at some stage during the course of their disease. These recommendations were reviewed in 2013, and the evidence-based guidelines suggest that in Australia RT is the treatment of choice for 48.3% of notifiable cancers (7) .
The last assessment of the RT situation in Lithuania was performed in 2001, in the QUARTS Project (Quantification of Radiation Therapy Infrastructure and Staffing Needs), initiated by the European Society for Therapeutic Radiology and Radiation Oncology (ESTRO) (8, 9) . Over the past decade, there have been enormous changes in the delivery of RT from two-dimensional and three-dimensional (3D) to intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) treatments using the greatly improved accuracy of CT simulation, multileaf collimators, etc. These complicated methods require more and more material resources, but according to some studies (10, 11) the costs of external RT constitute only 5% of the total costs for oncology services. However, an important factor influencing the choice of treatment modalities is the reimbursement system in Lithuania.
Without doubt, since the beginning of this century, RT has undergone many qualitative and structural changes. Projects, funded by the European Union in Lithuania, helped to purchase the major part of the diagnostic and treatment equipment. During the recent thirteen years, the number of linacs in Lithuania has increased 5.5 times; all cobalt machines were dismantled and not used any more.
The aim of this study was to estimate the situation of RT in Lithuania and to review the changes of RT productivity, equipment, workload, and RT service cost over the 13-year period from 2001 to 2014; to compare the current situation with other countries; and to predict the future demand for linacs until the year 2025. This is necessary for the rational planning of our financial resources in the future, and thereby ensuring the accessibility and quality of the RT services provided for patients. This is because the results of the QUARTS Project seem to have had a valuable impact on the government decisions.
MATERIALS AND METHODS
An electronic questionnaire was prepared and sent to all 4 RT centres in Lithuania. The data were collected for the calendar years of 2011 and 2014. The questionnaire consisted of 4 blocks of questions: general information about patients (numbers of patients treated, cancer types); RT methods applied; equipment owned; costs of RT services (only in the questionnaire of 2011).
The response rate was 100%. In order to identify contradictory data or to obtain missing information, an individual, standardised verbal survey was carried out (contacting by phone). The data published on the websites of the institutions were used as well.
Information about the RT situation in Lithuania in 2001 was obtained from the QUARTS Project participants.
Data of other countries from the published literature and the results of the ESTRO QUARTS (8) and HERO projects (12) , as well as documents and technical reports published in the official websites of international organisations (ESTRO, World Health Organisation (WHO), International Atomic Energy Agency (IAEA), etc.) were used. We selected the literature and reports relevant to the objective and methodology.
The article includes external beam RT data; we did not include benign indications, non-melanoma skin cancer, and paediatric cancer. The calculations of the external RT application level in the country included only primary patients. The RT utilisation rate is described as the number of new cases of cancer treated using RT per year, divided by the number of newly registered cases of cancer during that year. The numbers of new cases of cancer were obtained from the data of the Lithuanian Cancer Registry (the last report presents 2012 data) (1) .
The assessment of the workload for equipment, the number of patients, was calculated as the sum of primary and repeat therapy patients who received RT services in the calendar year.
Evaluating the RT cost, we used the cost structure and calculation methods mentioned in the literature (13, 14) .
The assessment of linacs demand in 2025 was based on the Australian (7, 15, 16) model (414 pts/ linac/year; additional 10% capacity in linac numbers to negate increase in the waiting times for treatment; a 25% re-treatment rate). For cancer incidence projections, the Globocan database was used (17).
RESULTS

Current situation of external beam radiotherapy in Lithuania
RT services in Lithuania are provided by 4 public healthcare institutions, two of which are established in the major cities and have 69% of patients per year. The other 2 RT centres are about three to four times smaller, regarding the number of patients treated as well as the number of linacs.
On the average, one RT centre in the country provides treatment for 1,702 patients per year (pts/ year). It is estimated that 64% of RT services are delivered within the outpatient setting.
In 2012 the number of new cancer cases was 17,734 (1) . Approximately 32.6% of all newly diagnosed patients were treated with external beam RT (non-melanomatous skin cancer and benign conditions were excluded) alone or in combination with other treatment modalities.
In 2014 the five most frequent cancers (66%) treated by RT were the following: breast, prostate, gynaecological, head and neck, lung cancers (Table 1). In comparison with the 2001 data, prostate and breast cancer patients treated by RT increased, especially prostate patients -more than 80%; other cancer patients decreased. Figure 1 shows an overview of RT equipment units in 2001-2014. In 2014 there were 11 linacs in the country: two major oncology centres owned 4 units each and the two smaller had 1 and 2 units, respectively, i. e. the largest centres had 73% of the entire RT infrastructure. IMRT practices were established in three centers and volumetric modulated arc therapy (VMAT) or stereotactic RT in two of them. 73% of linacs were capable of IGRT, while only 27% were equipped with kilovoltage cone-beam computed tomography (CBCT).
Equipment
There was a decrease in the number of orthovoltage treatment units, from 11 in 2001 to 4 in 2014. Currently these machines are only used for treatments of some skin tumours and other superficial lesions. The RT centres owned 4 simulators. There 
Cost of radiotherapy
The costs of RT departments were evaluated according to cost inputs used by other studies (13, 14) , and the results were compared with those of the year 2001 ( Table 2) . Both in 2011 and in 2001, the major cost drivers included the cost of equipment (purchases, depreciation, maintenance) and personnel salaries. In 2001, personnel costs were the most important cost component of an RT department, while in 2011 equipment costs were most important (78% of all these costs were for linacs purchasing and maintenance). Maintenance of equipment accounted for about 17% of all costs within the equipment category.
In total, the average cost per patient for RT treatment was EUR 974, that is 7.5 times more than that in the year 2001 (in 2001 it was EUR 129). The cost varies widely from one delivery method to the next one. Also, it depends on the institution size, e. g. in small institutions (departments treating <1,000 pts/year) the cost per patient was higher by more than 80%. So, looking from an economic point of view, the cost effectiveness applies to RT centres that treat more than 1,000 new patients annually, as is shown in other countries (9) .
Reimbursement system
Lithuania has a compulsory health insurance system, which means that residents of Lithuania are obliged to obtain health insurance coverage (i. e. pay compulsory health insurance contributions). With respect to the insured, the State guarantees healthcare services compensated by the Compulsory Health Insurance Fund.
The Ministry of Health establishes the appraisement for radiotherapy services provided by health institutions. The costs of expensive examinations and procedures performed during the episode of the active in-patient treatment are included in the total cost of healthcare service and are not reimbursed separately. An average reimbursement by the health institution for one treated patient with 3D conformal RT is 571 EUR; and for IMRT it is EUR 860. Obviously, institutions suffer losses providing RT services.
DISCUSSION
Comparing the current survey data with the data from Western countries or published optimal benchmarks, it is clear that the Lithuanian RT infrastructure is still below the average. According to our data, the actual RT utilisation rate in Lithuania was 32.6%, and it is relatively low when compared with the developed countries (Fig. 2)  (4, 15, 18 ). When compared with the Australian evidence-based estimation of the optimal RT utilization rate of 48.3% (7), or with the benchmark rate of the neighbouring country Poland (53.4%) (5), there is a significant shortfall between the optimal rate and the proportion of patients currently treated with RT. The HERO study (19) shows that the optimal utilization rate for Lithuania should be 51.5%. The most common tumour sites treated by RT were breast and prostate cancer cases. The numbers of these cancer sites increased during the last 10 years, but others (gynaecological, head and neck, lung cancer) decreased. This could be influenced by the following: the changes in cancer morbidity trends of some cancer sites (e. g. large increase of prostate cases; on the other hand, lung cancer cases decreased or stabilised); activity of cancer prevention and control programmes; implementing new, modern, and accurate RT technologies; changing treatment techniques and recommendations; the preference of the physician for one therapeutic option over alternatives; internal policy of health institutions and benchmarking; etc.
In Lithuania there were 3.7 linacs per million inhabitants. It does not meet the guidelines as developed by IAEA (20) and ESTRO (8, 9) . Western European countries reached this index ten years ago (21) . However, according to the data of the HERO study (19) , Lithuania surpasses such Eastern European countries as Estonia and Poland, but falls behind the Czech Republic, Hungary, and Slovenia.
ESTRO recommends that Lithuania has 4.6 lin acs per million population (9) , which is 14 units. Only 79% of this level were reached in 2014. How ever, the overview of the latest reports and recom mendations for linac workload (11, 16) concludes that the number of treatment units within Lithuania does not ensure accessibility of RT services and treatment quality.
For planning RT needs for 2025, three linacs demand scenarios were estimated based on the RT utilisation rate (Table 3) . This prognosis was made on the basis of the Australian principal calculation criteria (15, 16) . We did not find an official national prognosis of new cancer cases, so we used the Globocan database (17). It predicted a significant reduction of new cancer cases in 2025. This raises some suspicion. In order to make more precise linac requirements in the future, more accurate calculations are required, including cancer trends for each cancer site. The workload of linacs during recent years has been significantly reduced due to the increasing number of machines. But the workload exceeds the median number in European countries (419 treatment courses per MV unit) (12) , international recommendations, and the data of other countries (18, (21) (22) (23) (Table 4 ). The cost of RT depends on treatment modality, treatment intent (for cure or palliation), localisation of the primary site of cancer, stage, and other factors. In this survey, we calculated the average RT treatment costs in RT centres per calendar year. Our result is much lower than the average cost calculated by other studies, e. g. Ploquin and Dunscombe performed cost metaanalysis in which the mean normalized cost in 2005 was EUR 3.239 (14) ; in the recent Ireland study, the cost of traditional RT for rectal cancer in 2012 was EUR 3.609 (24) . Certainly, there are calculation errors due to methodological differences, but we can see common tendencies and make a comparison and come to preliminary conclusions. The investigation data shows that the reimbursement system in Lithuania is improper and does not cover treatment expenses. So, health institutions are not willing to provide RT services, and this could be one of the reasons for the low RT utilisation rate.
In order to lower RT treatment costs, it is necessary to increase the number of outpatients. Despite the fact that in the literature RT is described as a cost-effective treatment, it requires a high initial capital investment and has high on-going operating costs. Consequently, radiation treatment should be centralized in regional cancer centres (with more than 1,000 RT pts/year), especially for middle income countries as Lithuania and where distances to RT centres are not longer than 200 km.
In conclusion, during the recent thirteen years, RT services in Lithuania have dramatically improved, but we are still behind the average of European countries and benchmark rates. This potential need for additional new equipment and the workforce required to support it represents a significant challenge over the coming years and needs to feed into trust capital planning and workforce strategies as early as possible. The reimbursement system in the country is not in favour of RT centres. In order to raise the RT utilization rate, the reimbursement mechanism has to be reviewed and optimised. We think that this overview of the Lithuanian RT infrastructure will help to assess the current situation and continue the successful development of the RT services by increasing their accessibility and high quality.
